Skip to content
Study details
Enrolling now

A Study of LY4086940

Eli Lilly and Company
NCT IDNCT06945419ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

201

Study length

about 1 year

Ages

18–65

Locations

5 sites in FL, GA, TX

About this study

Researchers are testing a treatment called LY4086940 in people who are healthy, overweight or obese, or have type 2 diabetes. The trial will last about 372 days and involve visits to the clinic over several weeks. It is evaluating how safe and well-tolerated this treatment is.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take LY4086940
  • 2.Take Placebo
PhasePhase 1
Primary goalNumber of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4086940, Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4086940

Body systems

Endocrinology